Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Sage Therapeutics, Inc. (SAGE) shares ended the last trading session 35.4% higher at $9.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.8% loss over the past four weeks.The stock rallied after the company announced that Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics through a tender offer of $8.50 per share in cash, totaling around $561 million. Additionally, shareholders will receive a non-tradable contingent value right (CVR) worth up to $3.50 per share, bringing the total potential value of the deal to $12 per share in cash, or approximately $795 million.The transaction is expected to be closed in the third quarter of 2025, subject to customary closing conditions.This company is expected to post quarterly loss of $0.96 per share in its upcoming report, which represents a year-over-year change of +43.5%. Revenues are expected to be $17.34 million, up 100.5% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Sage Therapeutics, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Sage Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Compugen (CGEN), finished the last trading session 0.6% higher at $1.65. CGEN has returned 18% over the past month.Compugen's consensus EPS estimate for the upcoming report has changed +82.9% over the past month to -$0.07. Compared to the company's year-ago EPS, this represents a change of -250%. Compugen currently boasts a Zacks Rank of #3 (Hold).7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sage Therapeutics, Inc. (SAGE): Free Stock Analysis Report Dr. Reddy's Laboratories Ltd (RDY): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report ArcelorMittal (MT): Free Stock Analysis Report MSC Industrial Direct Company, Inc. (MSM): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report fuboTV Inc. (FUBO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks